C4 Therapeutics Management
Management criteria checks 2/4
C4 Therapeutics' CEO is Andrew Hirsch, appointed in Sep 2020, has a tenure of 5.25 years. total yearly compensation is $5.24M, comprised of 12.7% salary and 87.3% bonuses, including company stock and options. directly owns 0.44% of the company’s shares, worth $829.37K. The average tenure of the management team and the board of directors is 2.4 years and 8.4 years respectively.
Key information
Andrew Hirsch
Chief executive officer
US$5.2m
Total compensation
| CEO salary percentage | 12.69% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.4yrs |
| Board average tenure | 8.4yrs |
Recent management updates
Recent updates
Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price
Dec 17
Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss
Nov 26C4 Therapeutics, Inc. (NASDAQ:CCCC) Held Back By Insufficient Growth Even After Shares Climb 33%
Sep 05C4 Therapeutics, Inc. (NASDAQ:CCCC) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Jul 11We Think C4 Therapeutics (NASDAQ:CCCC) Needs To Drive Business Growth Carefully
Jun 20Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%
Apr 18C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here
Mar 10C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
Mar 04C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 33% Share Price Plunge Could Signal Some Risk
Nov 15C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout
Nov 06We're Not Very Worried About C4 Therapeutics' (NASDAQ:CCCC) Cash Burn Rate
Oct 02Analysts' Revenue Estimates For C4 Therapeutics, Inc. (NASDAQ:CCCC) Are Surging Higher
Aug 09C4 Therapeutics, Inc.'s (NASDAQ:CCCC) 41% Share Price Surge Not Quite Adding Up
Aug 03Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)
May 12C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched
Mar 01Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts
Feb 29C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Feb 24New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)
Nov 03Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week
May 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$119m |
| Jun 30 2025 | n/a | n/a | -US$112m |
| Mar 31 2025 | n/a | n/a | -US$103m |
| Dec 31 2024 | US$5m | US$665k | -US$105m |
| Sep 30 2024 | n/a | n/a | -US$105m |
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$126m |
| Dec 31 2023 | US$4m | US$639k | -US$132m |
| Sep 30 2023 | n/a | n/a | -US$135m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$131m |
| Dec 31 2022 | US$3m | US$614k | -US$128m |
| Sep 30 2022 | n/a | n/a | -US$107m |
| Jun 30 2022 | n/a | n/a | -US$99m |
| Mar 31 2022 | n/a | n/a | -US$95m |
| Dec 31 2021 | US$952k | US$580k | -US$84m |
| Sep 30 2021 | n/a | n/a | -US$80m |
| Jun 30 2021 | n/a | n/a | -US$82m |
| Mar 31 2021 | n/a | n/a | -US$73m |
| Dec 31 2020 | US$21m | US$168k | -US$66m |
Compensation vs Market: Andrew's total compensation ($USD5.24M) is above average for companies of similar size in the US market ($USD1.48M).
Compensation vs Earnings: Andrew's compensation has increased whilst the company is unprofitable.
CEO
Andrew Hirsch (54 yo)
Mr. Andrew J. Hirsch, M.B.A., is Independent Director of Akamis Bio Limited from August 2025. He is the President of C4 Therapeutics, Inc since September 14, 2020 and has been its Chief Executive Officer s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.3yrs | US$5.24m | 0.44% $ 829.4k | |
| Co-Founder | no data | US$176.63k | 0.36% $ 674.8k | |
| CFO & Treasurer | 2.3yrs | US$2.20m | 0.025% $ 47.8k | |
| Chief Medical Officer | 2.4yrs | US$2.31m | 0.022% $ 41.4k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Accounting Officer | 2.3yrs | no data | 0.0046% $ 8.8k | |
| Chief Scientific Officer | 1.2yrs | no data | 0.014% $ 26.6k | |
| Senior Manager of Investor Relations | no data | no data | no data | |
| Chief Legal Officer & Corporate Secretary | 5.4yrs | US$3.38m | 0.022% $ 41.1k | |
| Chief People Officer | 4.9yrs | no data | 0.023% $ 42.9k | |
| Senior Vice President of Strategic Alliances & Business Development | 9.8yrs | no data | no data | |
| Consultant | 1.2yrs | US$1.53m | 0.087% $ 164.5k |
Experienced Management: CCCC's management team is considered experienced (2.4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 5.2yrs | US$5.24m | 0.44% $ 829.4k | |
| Co-Founder | 10yrs | US$176.63k | 0.36% $ 674.8k | |
| Co-Founder & Member of Scientific Advisory Board | 9.1yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 9.1yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.4yrs | no data | no data | |
| Independent Chairman | 1.5yrs | US$346.20k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 8.4yrs | no data | no data | |
| Independent Director | 3.8yrs | US$191.63k | 0.0059% $ 11.1k | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
Experienced Board: CCCC's board of directors are considered experienced (8.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/31 17:19 |
| End of Day Share Price | 2025/12/30 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
C4 Therapeutics, Inc. is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | Barclays |
| Chi Meng Fong | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |